Objective: The aim of our study was to determine the rate of participation in genetic testing, to determine the reasons for non-participation and to identify the factors affecting participation in BRCA genetic testing for high-risk patients. Methods: This study was performed through a retrospective review of 804 individuals who underwent genetic counseling for BRCA1/2 gene mutations at Seoul National University Bundang Hospital between July 2003 and September 2012. Results: In total, 728 (90.5%) individuals underwent BRCA1/2 mutation screening after the initial genetic counseling; 88.2% of 647 probands and 100% of 157 family members were screened. In multivariate analysis, family history of breast cancer and younger age were independent variables affecting participation in genetic testing. Of the 132 people who initially declined genetic testing, 58 (43.9%) postponed the decision, 30 (22.7%) needed time to discuss the issue with family members, 22 (16.7%) did not want to know if they had a BRCA1/2 mutation, and 22 (16.7%) declined the test because of financial problems. When analyzing refusal of testing according to the time period before and after the implementation of national health insurance coverage for BRCA1/2 genetic testing, the critical reason given for refusal was different. After insurance coverage, refusal for financial reason was decreased from 61.1 to 9.6%. Conclusions: A family history of breast cancer and a younger age were important factors associated with participation in genetic testing. National health insurance decreased the proportion of individuals who did not participate in testing owing to a financial reason. In genetic counseling, we have to understand these issues and consider several factors that may influence an individual's decision to be tested.
Introduction
Since the identification of the BRCA1 gene in 1994 and the subsequent continued study of breast/ovarian cancer, the relationship between genes such as BRCA2, TP53, PTEN, LKB1 and MSH2/MLH1 and hereditary breast cancer has been discovered (1) (2) (3) . Among these, patient with the cancer but also the family members who are not yet affected with cancer. However, owing to psychosocial adverse effects that might affect the family and owing to possible social discrimination, it is not easy to decide whether counselees will undergo genetic testing to confirm the presence of a gene mutation (5) (6) (7) (8) . Genetic testing has advantages and disadvantages in various aspects as well as psychosocial issues. Therefore, factors affecting the participation rate and the utility of genetic testing are reported to be different among studies and groups (9, 10) .
This study aimed to determine the rate of participation in the BRCA1/2 genetic test, to identify the factors affecting a person's decision to undergo a BRCA1/2 genetic test, and to investigate the reasons for refusal for those who declined the genetic test.
Patients and methods
Between July 2003 and September 2012, a total of 804 individuals underwent genetic counseling for hereditary breast and ovarian cancer at the Seoul National University Bundang Hospital. All individuals met at least one of the following testing criteria for BRCA gene mutation screening: breast cancer patients with a family history of breast or ovarian cancer within the third degree, the early onset of breast cancer (age at diagnosis ≤40 years), bilateral breast cancer, multiple organ cancer, male breast cancer or family members of BRCA mutation carrier.
In our institution, the genetic counseling for informed consent was conducted by breast surgeon and professionally trained nurse. The counseling contents include taking a personal and family history; determining cancer risk and risk of carrying a mutation; educating about genetics of hereditary breast cancer, genetic testing methods, cost and the meaning of the results; discussing the benefits and risks of genetic testing, confidentiality issues and importance of sharing the testing results with family members. Among 804 individuals with genetic counseling, 728 individuals gave written informed consent and underwent genetic testing for BRCA mutation. Those who underwent genetic testing had post-test counseling to discuss the test results. For those who declined genetic testing after genetic counseling, we offered a simple questionnaire asking them to choose one of the following reasons for refusal: 'I will postpone the decision' (delayed decision), 'I will decide after a discussion with my family' (discussion with family), 'I will have a screening exam done more often without the genetic test' (screening without genetic test) and 'The testing fee is too expensive' (financial hardship). We provided those who initially declined the test with another opportunity by giving them a reminder about the genetic test when they came to the outpatient clinic for follow-up.
Clinical data were collected through a medical record review, and it included the clinicopathological features, personal and family history of breast and ovarian cancer, socioeconomic status and social history. This study was reviewed and approved by the Institutional Review Board of Seoul National University Bundang Hospital (IRB# B-1301/186-112).
Data were analyzed by using the SAS software version 9.2 (SAS institute, Cary, NC, USA). Comparison of the means of continuous variables was performed by using the Student's t-test, univariate comparison of all categorical variables was performed by using the χ 2 test, and multivariate analysis was performed by using logistic regression analysis. In the multivariate analysis, factors that were strongly related to one another were excluded. For factors that were found to be rare events, Firth's correction was used to reduce bias. A P value of <0.05 was considered to be statistically significant. All significance tests were two-sided.
Results
The mean age of all 804 individuals was 43.9 years (range, 20-83 years). Among the 804 individuals who underwent genetic counseling, 728 proceeded with genetic testing; therefore, the rate of participation in the genetic test was 90.5% (728/804). Of all 804 individuals, the number of probands (index patients) was 647, and among them, 571 (88.2%) underwent the genetic test. The number of family members of probands was 157, and all of them received genetic counseling and genetic testing (Fig. 1) . Among the probands, a univariate analysis was performed between the group that underwent genetic testing (the test group) and the group that did not have genetic testing after genetic counseling (the no-test group) ( Table 1 ). The mean age of the test group at the time of receiving genetic counseling was found to be 43.2 years (range, 26-69 years), which was younger than that of the no-test group 45.8 years (range, 20-83 years) (P = 0.058). There was no difference in family history of breast cancer or ovarian cancer, bilateral breast cancer, breast and ovarian cancer or multi-organ cancer between the two groups. Within the test group, the rate of patients with breast cancer diagnosed before age 40 years was significantly higher than the rate of the no-test group (57.1 and 42.1%, respectively; P = 0.014). Other factors such as marital status, presence of children, menstrual status, educational level and economic status were not significantly different between the two groups.
Multivariate logistic regression analysis revealed that individuals aged 40 years or less were more likely to undergo genetic testing [odds ratio (OR) = 3.205, 95% confidence interval (CI) = 1.550-6.622, P = 0.002]. Individuals who had a family history of breast cancer were also more likely to undergo genetic testing (OR = 1.963, 95% CI = 1.024-3.764, P = 0.042) ( Table 2) .
A total of 132 affected individuals declined the genetic test immediately after genetic counseling. The most common for refusal was 'I will postpone the decision' (delayed decision) which was answered by 58 individuals (43.9%), and the second most common answer was 'I will decide after a discussion with my family' (discussion with family), which was answered by 30 individuals (22.7%) (Fig. 2) . Among 132 individuals who declined genetic testing immediately after genetic counseling, 56 underwent the genetic test subsequently. When analyzing the data according to the reason for refusing genetic testing, we found that the participation rate was the highest with 59.1% (13/22) in the group complained of the financial hardship, and the median time taken until conducting the genetic test was 6.2 months (range, 0.1-27.5 months). The group of individuals who postponed the decision had the lowest rate of conducting the genetic test, at 36.2% (21/58), and the median time taken until the genetic test for this group was 0.5 months (range, 0.1-10.8 months) ( Table 3) .
We also analyzed refusal of testing according to the time period before and after the implementation of national health insurance coverage (18 August 2005) for BRCA1/2 genetic testing. Among 647 probands who received a genetic counseling, prior to national health insurance coverage, 18 of 58 individuals refused the genetic testing initially, 10 individuals underwent the genetic testing later, and 4 of 50 (8.0%) individuals with the genetic testing were confirmed as a BRCA mutation finally. After national health insurance coverage, 114 of 589 did not uptake the genetic testing initially, 46 individuals underwent the genetic testing subsequently, and 71 of 521 (13.6%) individuals had a BRCA mutation finally. Prior to national health insurance coverage, initial refusal rate was 31.0% and 11 of the 18 individuals (61.1%) refused the genetic test owing to financial hardship, and this group represented the largest percentage of refusals. However, after national health insurance coverage, initial refusal rate was 19.4% and only 11 of the 114 (9.6%) declined the test for financial reasons; this represented the smallest percentage among all reasons for refusal (Fig. 3) .
Discussion
This is the first study on a relatively large scale that evaluated the rate of participation in BRCA1/2 genetic testing and analyzed factors influencing the decision to get this genetic test in Korea. We also investigated the reason for refusal for those participants who declined the genetic test after genetic counseling. In addition, at the same time, this is the first study to investigate both the rate of participation in BRCA1/2 genetic testing for those who initially declined the genetic test immediately after counseling and the time taken until conducting the test when these subjects were followed up.
The rate of participation in genetic testing among the high-risk group of HBOC following genetic counseling was high, at 90.5% of all 804 patients and 88.2% of probands. The analysis of factors affecting participation in genetic testing in this study revealed that age (40 years or less) and family history of breast cancer were statistically significant factors. When analyzing the reason for those who declined the test, the most common reason for refusal was postponing the decision, while the least common reasons for refusal were financial hardship and willingness to undergo a screening done without the genetic test. However, when we followed up these patients, 42.4% (56/132) of subjects who initially declined testing underwent the genetic test later. Through this result, we learned of the importance of follow-up for the high-risk group of hereditary breast cancer patients who initially refuse genetic testing. Genetic counseling must be performed prior to conducting the genetic test. The goals of genetic counseling are to deliver the risk of the cancer and to point out the risks, advantages and limitations of the genetic test. Counseling also aims to assist a person in making a voluntary decision through a clear explanation of the risk of hereditary disease and its treatment method (11) (12) (13) (14) . Furthermore, specialized genetic counseling has an influence in increasing a patient's level of knowledge of hereditary breast cancer, decreasing anxiety and increasing the rate of participation in the genetic test (15) (16) (17) (18) . The complexity of genetic counseling contents is an obstacle for an individual trying to have a thorough understanding of the risk and necessity of the test. A variety of websites and computer-based decision aids can be used to compensate for this obstacle (19, 20) . Consequently, our center is making an effort to increase patients' level of knowledge and reduce their anxiety by using genetic counseling brochures and genetic counseling animation. This can play a role in increasing the rate of participation in genetic testing. In addition, to help in sharing the result with family members, we provide every patient who was identified as a BRCA mutation a 'letter to family member', which is a summary of basic information about hereditary breast cancer/ovarian cancer and the necessity of the genetic test for family members of probands. Despite this effort, however, not many family members visit the study center to receive genetic counseling. Furthermore, most of these individuals are those who have already decided to conduct the genetic test after having read the 'letter to family member' and after having a discussion with family. For this reason, all 157 individuals of family members underwent the genetic test, and therefore, they were excluded from the main analysis of this study. The analysis of factors affecting participation in genetic testing in this study revealed that age (40 years or less) and family history of breast cancer were statistically significant factors. There have been a large number of previous studies regarding a hypothetical circumstance in which the genetic test would be performed or not (21) (22) (23) (24) (25) . There have not been many studies targeting an actual group of patients at high risk for hereditary breast cancer. Armstrong et al. (6) reported that the Ashkenazi Jewish ethnicity was a factor with significant influence among 251 individuals who participated in a breast/ovarian cancer risk program. From a study of 172 individuals from families with hereditary breast cancer, Biesecker et al. (26) reported that age over 40 years was the significant factor in conducting genetic testing. Ropka et al. (9) discovered that a personal history of breast cancer and a family history of breast cancer were the significant factors in conducting the genetic test; their results came from a systematic review of a hypothetical study and a observational study, but the significance was found to be rather higher in the hypothetical study than it was in the observational study. Therefore, our study is worthwhile because it is a study on a large scale studying 804 individuals in a high-risk group for hereditary breast cancer.
As previously mentioned, a large number of studies have been performed regarding the rate of participation in BRCA genetic testing and factors that influence testing, but there are not many studies regarding the reasons for declining the BRCA genetic test. Geer et al. reported health insurability for self or family as a majority reason for not conducting the genetic test. In addition, cost, emotional impact on self or family, no perceived benefit and time commitment were also reported (27) . Hartenbach et al. (28) reported anxiety, potential discrimination, and cost as factors that were obstacles to genetic testing. Godard et al. (10) reported that a complaint of psychological effects was the main reason for declining genetic testing, and other reasons included a limited ability to travel, lack of time and personal issues. The present study, unlike the study mentioned above, included financial circumstances along with behavior pattern in the reasons for refusal of genetic testing. Considering the results of our study during patient follow-up will likely increase the rate of participation in genetic testing.
Since 18 August 2005, national health insurance in Korea has provided a support for the cost of genetic testing of patients at high risk for hereditary breast cancer. This has reduced the cost burden on an individual by one-tenth, from USD 680 to USD 72. Among reasons for declining the test, the rate of those who initially refused the test owing to financial hardship was the highest, at 61.1% before the change in insurance coverage. After the change in insurance coverage, this reason for refusal became the least common reason, at 9.6%. This result showed that support at the governmental level is much needed to facilitate the management of groups of patients at high risk for cancer and to facilitate proactive prevention (29) .
Although this study proposed a variety of analysis, it was limited in that it was a retrospective study. In addition, the study could have been improved by including psychological issues as categories for the reason of refusal of genetic testing.
Our study showed a high rate of genetic testing participation in a group of patients at high risk for HBOC. We attribute this result to the fact that we offered systematic genetic counseling and follow-up for the no-test group of patients at high risk for HBOC, and to the fact that the cost of genetic testing was low because it is covered by national health insurance. In our study, the influencing factors on participating in the genetic test were age (40 years or less) and family history of breast cancer. Therefore, age, family history of cancer and various factors that affect the decision to undergo a genetic test should be considered in systematic genetic counseling.
